jumonji domain containing 6, arginine demethylase and lysine hydroxylase | 1.14.11.- Histone demethylases | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

jumonji domain containing 6, arginine demethylase and lysine hydroxylase

Target not currently curated in GtoImmuPdb

Target id: 2892

Nomenclature: jumonji domain containing 6, arginine demethylase and lysine hydroxylase

Family: 1.14.11.- Histone demethylases

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 403 17q25 JMJD6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase
Mouse - 403 11 E2 Jmjd6 jumonji domain containing 6
Rat - 403 10q32.3 Jmjd6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase
Gene and Protein Information Comments
For the human JMJD6 we show details of protein isoform 2. Isoform 1 is slightly longer with 414 amino acids (with ref seq NP_001074930).
Previous and Unofficial Names
bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 | jumonji domain containing 6 | phosphatidylserine receptor | PSR | PtdSerR
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
General Comments
JMJD6 is a dual arginine demethylase and lysyl hydroxylase of histone and nonhistone proteins [2-3]. It is iron- and 2-oxoglutarate-dependent and is the only known histone arginine demethylase in humans. JMJD6 catalyses the demethylation of H3R2me2, H4R3me2 and H4R3me1 [2]. As a histone arginine demethylase JMJD6 upregulates target gene transcription, and is one of the proteins encoded in the chromosome 17q21-ter gain genetic variant found in human neuroblastoma tissues (and which is a negative prognostic indicator) [1]. As a neuroblastoma tumorigenesis factor JMJD6 is a novel therapeutic target for this cancer [4].

References

Show »

1. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H et al.. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340 (25): 1954-61. [PMID:10379019]

2. Chang B, Chen Y, Zhao Y, Bruick RK. (2007) JMJD6 is a histone arginine demethylase. Science, 318 (5849): 444-7. [PMID:17947579]

3. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, Nielsen ML, Schmitz C, Butler DS, Yates 3rd JR et al.. (2009) Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science, 325 (5936): 90-3. [PMID:19574390]

4. Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell J, Mayoh C, Ho N, Tee AE et al.. (2019) JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nature Comminications, 10. DOI: 10.1038/s41467-019-11132-w

How to cite this page

1.14.11.- Histone demethylases: jumonji domain containing 6, arginine demethylase and lysine hydroxylase. Last modified on 26/07/2019. Accessed on 20/10/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2892.